Cargando…
Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between pl...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567018/ https://www.ncbi.nlm.nih.gov/pubmed/23409150 http://dx.doi.org/10.1371/journal.pone.0056170 |
_version_ | 1782258643210600448 |
---|---|
author | Ji, Hezhao Li, Yang Liang, Binhua Pilon, Richard MacPherson, Paul Bergeron, Michèle Kim, John Graham, Morag Van Domselaar, Gary Sandstrom, Paul Brooks, James |
author_facet | Ji, Hezhao Li, Yang Liang, Binhua Pilon, Richard MacPherson, Paul Bergeron, Michèle Kim, John Graham, Morag Van Domselaar, Gary Sandstrom, Paul Brooks, James |
author_sort | Ji, Hezhao |
collection | PubMed |
description | Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between plasma and DBS is not absolute and varies according to viral load (VL), duration of HIV infection and antiretroviral therapy (ART) status. The plasma/DBS concordance is the highest when VL is ≥5,000 copies/ml and/or the patient has no ART exposure and/or when the duration of HIV infection is ≤2 years. Stepwise regression analysis revealed that VL is most important independent predictor for concordance of DBS with plasma genotypes. This is the first study to use next generation sequencing to identify discordance between DBS and plasma genotypes. Consideration should be given to VL, duration of infection, and ART exposure when interpreting DBS genotypes produced using next generation sequencing. These findings are of particular significance when DBS are to be used for clinical monitoring purposes. |
format | Online Article Text |
id | pubmed-3567018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35670182013-02-13 Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients Ji, Hezhao Li, Yang Liang, Binhua Pilon, Richard MacPherson, Paul Bergeron, Michèle Kim, John Graham, Morag Van Domselaar, Gary Sandstrom, Paul Brooks, James PLoS One Research Article Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between plasma and DBS is not absolute and varies according to viral load (VL), duration of HIV infection and antiretroviral therapy (ART) status. The plasma/DBS concordance is the highest when VL is ≥5,000 copies/ml and/or the patient has no ART exposure and/or when the duration of HIV infection is ≤2 years. Stepwise regression analysis revealed that VL is most important independent predictor for concordance of DBS with plasma genotypes. This is the first study to use next generation sequencing to identify discordance between DBS and plasma genotypes. Consideration should be given to VL, duration of infection, and ART exposure when interpreting DBS genotypes produced using next generation sequencing. These findings are of particular significance when DBS are to be used for clinical monitoring purposes. Public Library of Science 2013-02-07 /pmc/articles/PMC3567018/ /pubmed/23409150 http://dx.doi.org/10.1371/journal.pone.0056170 Text en © 2013 Ji et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Ji, Hezhao Li, Yang Liang, Binhua Pilon, Richard MacPherson, Paul Bergeron, Michèle Kim, John Graham, Morag Van Domselaar, Gary Sandstrom, Paul Brooks, James Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients |
title | Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients |
title_full | Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients |
title_fullStr | Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients |
title_full_unstemmed | Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients |
title_short | Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients |
title_sort | pyrosequencing dried blood spots reveals differences in hiv drug resistance between treatment naïve and experienced patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567018/ https://www.ncbi.nlm.nih.gov/pubmed/23409150 http://dx.doi.org/10.1371/journal.pone.0056170 |
work_keys_str_mv | AT jihezhao pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT liyang pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT liangbinhua pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT pilonrichard pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT macphersonpaul pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT bergeronmichele pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT kimjohn pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT grahammorag pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT vandomselaargary pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT sandstrompaul pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients AT brooksjames pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients |